Year: 2020
Type: article
Abstract: No single standard treatment exists for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)–positive breast cancers, because most of these patients have been ineligible for the pivotal trials of adjuvant trastuzumab.
DOI: 10.17615/5g5m-fr14
Authors: Winer, Eric P., Carey, Lisa A., Partridge, Ann H., Guo, Hao, Albain, Kathy S., Rugo, Hope S., Wolff, Antonio C., Barry, William T., Tolaney, Sara M., Shapira, Iuliana, Ellis, Matthew, Hudis, Clifford A., Yardley, Denise A., Marcom, P. Kelly, Burstein, Harold J., Moy, Beverly, Krop, Ian E., Overmoyer, Beth A., Dang, Chau T.
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: Genentech
OpenAlex ID: W4301208997